PRVB News and Press, Provention Bio Inc. From 02/22/23

Summary PRVB got its teplizumab approved last year. The molecule is a wonderful new addition to T1D therapy; however, it has been in development for decades. Thus, the patent angle worries me. I covered Provention Bio ( PRVB ) in June 2021, when I said that despite a 1...

Last year's downturn impacted a lot of companies otherwise performing relatively well. On the other hand, struggling or somewhat unproven corporations were hammered, probably much more so than the average. That opens up potentially lucrative opportunities for investors. Those stocks that can ...

Summary Tourlite Capital Management, LP is an asset management firm focused on long/short equity investing in public companies. Tourlite Fund, LP Founder Class returned 3.4% for the Fourth Quarter of 2022. Entering 2023, we continue to see the same downside risk to earnings in the e...

Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US PR Newswire Companies collaborating to expand access to TZIELD™ (teplizumab-mzwv), the first approved disease-modifying therapy for type 1 diabetes RED BANK, N.J. , Feb...

Provention Bio to Present at the SVB Securities Global Biopharma Conference PR Newswire RED BANK, N.J. , Feb. 8, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease...

Summary Received FDA approval of TZIELD for Stage 2 Type 1 Diabetes patients in November of 2022. Potential to increase market potential of TZIELD with ongoing phase 3 PROTECT study, which is being used for stage 3 newly diagnosed T1D patients. Results expected 2nd half of 2023. It ...

Provention Bio Announces Closing of Second Tranche with Hercules Capital to Support U.S. Commercial Launch of TZIELD® PR Newswire RED BANK, N.J. , Feb. 2, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical comp...

Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors PR Newswire RED BANK, N.J. , Jan. 5, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immu...

Summary After the FDA's approval of Tzield and with better-than-expected pricing, we are upgrading to a Buy rating. PRVB's pricing and approval bode well for the stock and de-risk owning it; however, we are neutral around the Q1-Q2 sales print due to uncertainty around market access. ...

Shares of Provention Bio (NASDAQ: PRVB) rose 30.3% in November, according to data from S&P Global Intelligence . The pharmaceutical company closed out October at $6.94 and opened November at $7. It rose to a 52-week high of $9.85 on Nov. 25 and closed out the month at $9.04. Its s...